Maria Abreu, MD, breaks down efficacy and safety data for dual-target co-antibody JNJ-4804, offering a potential new option for heavily pretreated UC patients.
Maria Abreu, MD
Advertisement
Maria Abreu, MD, is Executive Director of the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai.
Articles by Maria Abreu, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
How Dermatology PAs Can Master Rapid Diagnostic Recognition
2
STAT6, ITK Inhibitors, IL-31, & IL-18 Headline Burgeoning Pipeline in Atopic Dermatitis, with David Rosmarin, MD
3
Emerging Evidence in Atopic Dermatitis Management, With Harrison Nguyen, MD, MBA, MPH
4
Managing FCS: LPL-Targeted Therapy, Drug Rationalization, and Atherosclerosis Risk
5